Esler Murray, Eikelis Nina, Schlaich Markus, Lambert Gavin, Alvarenga Marlies, Kaye David, El-Osta Assam, Guo Ling, Barton David, Pier Ciaran, Brenchley Celia, Dawood Tye, Jennings Garry, Lambert Elisabeth
Baker Heart Research Institute, Melbourne, Australia.
Ann N Y Acad Sci. 2008 Dec;1148:338-48. doi: 10.1196/annals.1410.064.
Patients with panic disorder provide a clinical model of stress. On a "good day," free from a panic attack, they show persistent stress-related changes in sympathetic nerve biology, including abnormal sympathetic nerve single-fiber firing ("salvos" of multiple firing within a cardiac cycle) and release of epinephrine as a cotransmitter. The coreleased epinephrine perhaps originates from in situ synthesis by phenylethanolamine N-methyltransferase (PNMT). In searching for biological evidence that essential hypertension is caused by mental stress--a disputed proposition--we note parallels with panic disorder, which provides an explicit clinical model of stress: (1) There is clinical comorbidity; panic disorder prevalence is increased threefold in essential hypertension. (2) For both, epinephrine cotransmission is present in sympathetic nerves. (3) In panic disorder and essential hypertension, but not in health, single-fiber sympathetic nerve firing salvos occur. (4) Tissue nerve growth factor is increased in both conditions (nerve growth factor is a stress reactant). (5) There is induction of PNMT in sympathetic nerves. Essential hypertension exhibits a further manifestation of mental stress: there is activation of noradrenergic brain stem neurons projecting to the hypothalamus and amygdala. These pathophysiological findings strongly support the view that chronic mental stress is important in the pathogenesis of essential hypertension. A hypothesis now under test is whether in both disorders, under prevailing conditions of ongoing stress, PNMT induced in sympathetic nerves acts as a DNA methylase, causing the norepinephrine transporter (NET) gene silencing that is present in both conditions. PNMT can have an intranuclear distribution, binding to DNA. We have demonstrated that the reduced neuronal noradrenaline reuptake present in both disorders does have an epigenetic mechanism, with demonstrable reduction in the abundance of the transporter protein, the NET gene silencing being associated with DNA binding by the methylation-related inhibitory transcription factor MeCP2.
惊恐障碍患者提供了一个应激的临床模型。在没有惊恐发作的“好日子”里,他们表现出交感神经生物学中与应激相关的持续变化,包括异常的交感神经单纤维放电(心动周期内多次放电的“齐射”)以及作为共递质的肾上腺素释放。共同释放的肾上腺素可能源自苯乙醇胺N -甲基转移酶(PNMT)的原位合成。在寻找原发性高血压由精神应激引起这一有争议观点的生物学证据时,我们注意到它与惊恐障碍存在相似之处,惊恐障碍提供了一个明确的应激临床模型:(1)存在临床共病现象;原发性高血压中惊恐障碍的患病率增加了两倍。(2)对于两者而言,交感神经中都存在肾上腺素共传递。(3)在惊恐障碍和原发性高血压中而非健康状态下,会出现单纤维交感神经放电齐射。(4)在这两种情况下组织神经生长因子都会增加(神经生长因子是一种应激反应物)。(5)交感神经中会诱导PNMT表达。原发性高血压表现出精神应激的另一种表现:投射到下丘脑和杏仁核的去甲肾上腺素能脑干神经元被激活。这些病理生理学发现有力地支持了慢性精神应激在原发性高血压发病机制中起重要作用这一观点。目前正在测试的一个假设是,在这两种疾病中,在持续应激的普遍条件下,交感神经中诱导产生的PNMT是否作为一种DNA甲基化酶,导致这两种疾病中都存在的去甲肾上腺素转运体(NET)基因沉默。PNMT可以在细胞核内分布并与DNA结合。我们已经证明,这两种疾病中存在的神经元去甲肾上腺素再摄取减少确实有一种表观遗传机制,转运蛋白丰度明显降低,NET基因沉默与甲基化相关的抑制性转录因子MeCP2与DNA结合有关。